DOCSLIB.ORG

University of Groningen Hand Eczema Christoffers, Wianda

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
University of Groningen Hand Eczema Christoffers, Wianda University of Groningen Hand eczema Christoffers, Wianda IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2014 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Christoffers, W. (2014). Hand eczema: interventions & contact allergies. [S.n.]. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 10-10-2021 Hand eczema interventions and contact allergies Wietske Andrea Christoffers ISBN: 978-90-367-7355-3 (printed version) ISBN: 978-90-367-7354-6 (e-version) © W.A. Christoffers, Groningen, The Netherlands [email protected] All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without written permission from the author. Financial support for the publication of this thesis was provided by: AbbVie, Afdeling Dermatologie UMCG, ALK-Abelló BV, Almirall BV, BAP Medical BV, Combicare, Eucerin, Fagron BV, Galderma, GlaxoSmithKlineBV, La Roche-Posay, LEO Pharma, Novartis Pharma BV, Stichting Milieu en Arbeidsdermatologie, Studiefonds Dermatologie, Van Der Bend Medical Supplies, Waldmann BV, Will Pharma Cover design: Id Graficus, Assen, www.idgraficus.com, The Netherlands Layout: Id Graficus, Assen, www.idgraficus.com, The Netherlands Printing: GVO drukkers & vormgevers B.V., Ede, The Netherlands Hand eczema interventions & contact allergies Proefschrift ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen op gezag van de rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op maandag 24 november 2014 om 12:45 uur door Wietske Andrea Christoffers geboren op 29 april 1987 te Assen Promotor Prof. dr. P.J. Coenraads Copromotor Dr. M.L.A. Schuttelaar Beoordelingscommissie Prof. dr. T. Agner Prof. dr. T. Rustemeyer Prof. dr. W.J.C. Uter Paranymfen Jorinde Dries-Talman Tatiana Alexandra Vogel Contents Chapter 1 Introduction 8 Chapter 2 Cochrane review: Interventions for hand eczema (Short version) 30 Chapter 3 Evidence based dermatology – Hand eczema 104 Chapter 4 Drug survival of cyclosporine in the treatment of hand eczema: 134 a multicenter, daily use study Chapter 5 Patch test results of hand eczema patients: relation to clinical types 148 Chapter 6 Severe bullous allergic contact dermatitis caused by glycidyl 166 methacrylate and other acrylates Chapter 7 Two decades of occupational (meth)acrylate patch test results and 174 focus on isobornyl acrylate Chapter 8 Co-sensitization to ascaridole and tea tree oil 190 Chapter 9 The optimal patch test concentration for ascaridole as a sensitizing 198 component of tea tree oil Chapter 10 Discussion How to treat hand eczema in daily practice? 216 Summary 240 Nederlandse samenvatting 246 Dankwoord 254 Bibliografie 260 Curriculum Vitae 264 7 Chapter 1 8 chapter 1 Introduction Hand eczema: interventions & contact allergies Wietske Andrea Christoffers Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands 9 chapter A few million years ago, our ancestors decided to start walking on two legs, which made it easier for them to collect food from high branches and to use tools. Moreover, humans 1 standing upright appeared longer and more intimidating. Over the years, the proximal extremities developed for other functions, making it easier to conduct more precise tasks. Nowadays hands are an important part of the human body and play a prominent role in social interaction: they enable us able to greet each other, shake hands, and hug or caress each other. Hands appear even in proverbs: “Many hands make light work”, “One hand washes the other” or “The hand that rocks the cradle rules the world”. Hands are indispensable to our daily lives. Therefore, diseases affecting the hands, such as hand eczema, can have a tremendous impact on daily activities and the quality of life. Hand eczema, also called hand dermatitis, is an inflammatory skin reaction confined to the hands. It often manifests as a chronic and relapsing condition, involving pruritus and painful fissures. Although many patients suspect that allergies play a dominant role in their hand eczema, other factors like exposure to irritants such as water, detergents or oils are just as important. This thesis discusses the treatment options for patients with hand eczema; it features a Cochrane review regarding interventions for hand eczema and a practical therapeutic plan. We also discuss the relationship between hand eczema and allergic contact dermatitis. Finally, it highlights two relatively unknown contact allergens which can play a role in hand eczema: ascaridole and isobornyl acrylate. Epidemiology Hand eczema is a common condition. The 1-year prevalence in the general Swedish population was estimated at 4%, though when mild cases were also included the 1-year prevalence was as high as 10%.1 The incidence was around 5.5 per 1,000 persons. Approximately one third of patients with hand eczema developed symptoms before the age of 20.1 A Swedish population-based study gave a self-reported 1-year prevalence of hand eczema of 8% (females 10%, males 6%).2 The highest prevalence was reported among females aged between 19 and 40 years; this seemed to be related to an increased frequency of hand washing, nickel contact allergy and childhood atopic dermatitis.1 In a cross-sectional study among 1,501 Danish school children (aged 12-16 years), the self-reported life time prevalence for hand eczema was 9.2% and the 1-year prevalence was 7.3%, with a pre- ponderance in girls.3 Eczema was defined as itching, erythema, vesicles and/or papules and scaling localized to the fingers or finger webs, backs of hands or palms, and with a duration of at least two days. The clinically evaluated point-prevalence in these school children was 3.2%, with a borderline significant sex difference.1 The majority of epidemiology studies of hand eczema have been conducted in Scandina- vian countries and most are questionnaire based. Due to underestimation of mild cases or 10 recall bias, questionnaires might underestimate the true prevalence. However, investigating chapter large cohorts of “healthy” people for the diagnosis of hand eczema is expensive and very time- and labor consuming. Moreover, a recent study of Danish hairdressers’ apprentices 1 concluded that self-reporting of hand eczema is a valid method for estimating its prevalence with good sensitivity and very high specificity.4 Meding et al. validated the self-reported 1-year prevalence of hand eczema in car mechanics, dentists and office workers, based on questionnaires, interviews and clinical examinations.5 Meding also found a high specificity (96–99%), but a lower sensitivity (53–59%) for the use of a self-reporting questionnaire. Occupational hand eczema is one of the most frequently recognized occupational skin diseases.6 The incidence of notified hand eczema in occupational related cases (and thus probably more severe cases) is above 0.5-1.9 per 1,000 workers a year.7 In a large database of 1,504 Danish cases of occupational contact dermatitis, irritant contact dermatitis accounted for 70% of all cases; 68% of these were caused by wet work.8 Occupations that involve exposure to water, irritants or trauma are especially at risk for developing hand dermatitis. Cleaners, bakers, hairdressers and caterers are exposed to a lot of wet-work and are therefore prone to develop hand eczema, but one of the most investigated occupational risk groups are health care workers. In the Netherlands the self-reported 1-year prevalence of hand eczema among 1,232 health care workers was 12% (95% confidence interval 11–14) with a point-prevalence of 4.9% (95% confidence interval 3.8–6.3).9 Almost half of all questioned health professionals reported at least one symptom of hand eczema over the last three months. In this study population 1.7% of workers with hand eczema reported sick because of hand eczema in the past three months. These results were reproduced in 525 Taiwanese nurses: 75.6% of them reported symptoms of hand eczema, and 31.0% suffered from self-reported hand eczema.10 Young age, history of atopic dermatitis, frequent hand washing (>20 times/day) and wearing gloves longer than 5 minutes a day were risk factors for hand eczema, while frequent use of hand moisturizer (>3-4 times/day) had a protective effect. Other employees at risk for developing hand eczema are those at risk of occupational sensitization because they work with well known allergens. Examples of these are hairdressers11 with contact allergies for p-phenylenediamine (PPD), p-toluenediamine (PTD), and ammonium persulfate;12 dental workers for (meth)acrylates13 or line assembly workers for different allergens in glues or coatings.8,14 Clinical presentation of hand eczema and diagnostic strategy Hand eczema or hand dermatitis is primary an inflammatory skin reaction of the hands, although the feet and other body parts may also be affected.
Load more

Recommended publications
  • Dermatology DDX Deck, 2Nd Edition 65
    63. Herpes simplex (cold sores, fever blisters) PREMALIGNANT AND MALIGNANT NON- 64. Varicella (chicken pox) MELANOMA SKIN TUMORS Dermatology DDX Deck, 2nd Edition 65. Herpes zoster (shingles) 126. Basal cell carcinoma 66. Hand, foot, and mouth disease 127. Actinic keratosis TOPICAL THERAPY 128. Squamous cell carcinoma 1. Basic principles of treatment FUNGAL INFECTIONS 129. Bowen disease 2. Topical corticosteroids 67. Candidiasis (moniliasis) 130. Leukoplakia 68. Candidal balanitis 131. Cutaneous T-cell lymphoma ECZEMA 69. Candidiasis (diaper dermatitis) 132. Paget disease of the breast 3. Acute eczematous inflammation 70. Candidiasis of large skin folds (candidal 133. Extramammary Paget disease 4. Rhus dermatitis (poison ivy, poison oak, intertrigo) 134. Cutaneous metastasis poison sumac) 71. Tinea versicolor 5. Subacute eczematous inflammation 72. Tinea of the nails NEVI AND MALIGNANT MELANOMA 6. Chronic eczematous inflammation 73. Angular cheilitis 135. Nevi, melanocytic nevi, moles 7. Lichen simplex chronicus 74. Cutaneous fungal infections (tinea) 136. Atypical mole syndrome (dysplastic nevus 8. Hand eczema 75. Tinea of the foot syndrome) 9. Asteatotic eczema 76. Tinea of the groin 137. Malignant melanoma, lentigo maligna 10. Chapped, fissured feet 77. Tinea of the body 138. Melanoma mimics 11. Allergic contact dermatitis 78. Tinea of the hand 139. Congenital melanocytic nevi 12. Irritant contact dermatitis 79. Tinea incognito 13. Fingertip eczema 80. Tinea of the scalp VASCULAR TUMORS AND MALFORMATIONS 14. Keratolysis exfoliativa 81. Tinea of the beard 140. Hemangiomas of infancy 15. Nummular eczema 141. Vascular malformations 16. Pompholyx EXANTHEMS AND DRUG REACTIONS 142. Cherry angioma 17. Prurigo nodularis 82. Non-specific viral rash 143. Angiokeratoma 18. Stasis dermatitis 83.
    [Show full text]
  • Pattern of Pediatric Dermatoses in a Tertiary Care Centre in Karnataka
    Original Research Article Pattern of Pediatric Dermatoses in a Tertiary Care Centre in Karnataka Bangaru H1,*, Nanjundaswamy BL2 1Assistant Professor, 2Professor, Mysore Medical College & Research Institute, Mysore *Corresponding Author: Email: [email protected] Abstract Background: Skin diseases are major health problem in the pediatric age group and it reflects the status of health, nutrition, hygiene and personal cleanliness of a community. Objective: 1. To estimate the proportion of pediatric skin diseases. 2. To estimate and test the impact of age and sex on pediatric skin diseases 3. To prioritize the condition of skin diseases among pediatric age group. Inclusion criteria: All cases registered in outpatient records aged 0-18 years. Exclusion criteria: None. Materials and Methods: Study design: Retrospective study. Retrospective collection of data from the out patient records, of all children aged 0-18 years, who had attended as out-patient, in dermatology out-patient department, in Krishna Rajendra Hospital, Mysore, Karnataka. The diseases will be tabulated based on age, sex and etiology and results will be analysed. Sample size: With the incidence of pediatric dermatoses 9-37%, level of significance 5%, absolute allowable error 5%, using confidence interval approach, the sample size is 131-373. However, over a period of six months, 3753 pediatric case sheets have been considered for the study. Statistical method: Objective 1 is analysed through frequency and proportion, objective 2 is analysed through bivariate frequency technique using frequency, chi-square test and object 3 is addressed through frequency technique. Results: Out of 16500 out patients 3753 were children aged 0-18 years. Males (1984) were slightly more than females (1769) with male to female ratio of 1.12:1.
    [Show full text]
  • COVID-19 Mrna Pfizer- Biontech Vaccine Analysis Print
    COVID-19 mRNA Pfizer- BioNTech Vaccine Analysis Print All UK spontaneous reports received between 9/12/20 and 22/09/21 for mRNA Pfizer/BioNTech vaccine. A report of a suspected ADR to the Yellow Card scheme does not necessarily mean that it was caused by the vaccine, only that the reporter has a suspicion it may have. Underlying or previously undiagnosed illness unrelated to vaccination can also be factors in such reports. The relative number and nature of reports should therefore not be used to compare the safety of the different vaccines. All reports are kept under continual review in order to identify possible new risks. Report Run Date: 24-Sep-2021, Page 1 Case Series Drug Analysis Print Name: COVID-19 mRNA Pfizer- BioNTech vaccine analysis print Report Run Date: 24-Sep-2021 Data Lock Date: 22-Sep-2021 18:30:09 MedDRA Version: MedDRA 24.0 Reaction Name Total Fatal Blood disorders Anaemia deficiencies Anaemia folate deficiency 1 0 Anaemia vitamin B12 deficiency 2 0 Deficiency anaemia 1 0 Iron deficiency anaemia 6 0 Anaemias NEC Anaemia 97 0 Anaemia macrocytic 1 0 Anaemia megaloblastic 1 0 Autoimmune anaemia 2 0 Blood loss anaemia 1 0 Microcytic anaemia 1 0 Anaemias haemolytic NEC Coombs negative haemolytic anaemia 1 0 Haemolytic anaemia 6 0 Anaemias haemolytic immune Autoimmune haemolytic anaemia 9 0 Anaemias haemolytic mechanical factor Microangiopathic haemolytic anaemia 1 0 Bleeding tendencies Haemorrhagic diathesis 1 0 Increased tendency to bruise 35 0 Spontaneous haematoma 2 0 Coagulation factor deficiencies Acquired haemophilia
    [Show full text]
  • Therapies for Common Cutaneous Fungal Infections
    MedicineToday 2014; 15(6): 35-47 PEER REVIEWED FEATURE 2 CPD POINTS Therapies for common cutaneous fungal infections KENG-EE THAI MB BS(Hons), BMedSci(Hons), FACD Key points A practical approach to the diagnosis and treatment of common fungal • Fungal infection should infections of the skin and hair is provided. Topical antifungal therapies always be in the differential are effective and usually used as first-line therapy, with oral antifungals diagnosis of any scaly rash. being saved for recalcitrant infections. Treatment should be for several • Topical antifungal agents are typically adequate treatment weeks at least. for simple tinea. • Oral antifungal therapy may inea and yeast infections are among the dermatophytoses (tinea) and yeast infections be required for extensive most common diagnoses found in general and their differential diagnoses and treatments disease, fungal folliculitis and practice and dermatology. Although are then discussed (Table). tinea involving the face, hair- antifungal therapies are effective in these bearing areas, palms and T infections, an accurate diagnosis is required to ANTIFUNGAL THERAPIES soles. avoid misuse of these or other topical agents. Topical antifungal preparations are the most • Tinea should be suspected if Furthermore, subsequent active prevention is commonly prescribed agents for dermatomy- there is unilateral hand just as important as the initial treatment of the coses, with systemic agents being used for dermatitis and rash on both fungal infection. complex, widespread tinea or when topical agents feet – ‘one hand and two feet’ This article provides a practical approach fail for tinea or yeast infections. The pharmacol- involvement. to antifungal therapy for common fungal infec- ogy of the systemic agents is discussed first here.
    [Show full text]
  • Copyrighted Material
    Part 1 General Dermatology GENERAL DERMATOLOGY COPYRIGHTED MATERIAL Handbook of Dermatology: A Practical Manual, Second Edition. Margaret W. Mann and Daniel L. Popkin. © 2020 John Wiley & Sons Ltd. Published 2020 by John Wiley & Sons Ltd. 0004285348.INDD 1 7/31/2019 6:12:02 PM 0004285348.INDD 2 7/31/2019 6:12:02 PM COMMON WORK-UPS, SIGNS, AND MANAGEMENT Dermatologic Differential Algorithm Courtesy of Dr. Neel Patel 1. Is it a rash or growth? AND MANAGEMENT 2. If it is a rash, is it mainly epidermal, dermal, subcutaneous, or a combination? 3. If the rash is epidermal or a combination, try to define the SIGNS, COMMON WORK-UPS, characteristics of the rash. Is it mainly papulosquamous? Papulopustular? Blistering? After defining the characteristics, then think about causes of that type of rash: CITES MVA PITA: Congenital, Infections, Tumor, Endocrinologic, Solar related, Metabolic, Vascular, Allergic, Psychiatric, Latrogenic, Trauma, Autoimmune. When generating the differential, take the history and location of the rash into account. 4. If the rash is dermal or subcutaneous, then think of cells and substances that infiltrate and associated diseases (histiocytes, lymphocytes, mast cells, neutrophils, metastatic tumors, mucin, amyloid, immunoglobulin, etc.). 5. If the lesion is a growth, is it benign or malignant in appearance? Think of cells in the skin and their associated diseases (keratinocytes, fibroblasts, neurons, adipocytes, melanocytes, histiocytes, pericytes, endothelial cells, smooth muscle cells, follicular cells, sebocytes, eccrine
    [Show full text]
  • Statistical Analysis Plan
    Cover Page for Statistical Analysis Plan Sponsor name: Novo Nordisk A/S NCT number NCT03061214 Sponsor trial ID: NN9535-4114 Official title of study: SUSTAINTM CHINA - Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Document date: 22 August 2019 Semaglutide s.c (Ozempic®) Date: 22 August 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL Clinical Trial Report Status: Final Appendix 16.1.9 16.1.9 Documentation of statistical methods List of contents Statistical analysis plan...................................................................................................................... /LQN Statistical documentation................................................................................................................... /LQN Redacted VWDWLVWLFDODQDO\VLVSODQ Includes redaction of personal identifiable information only. Statistical Analysis Plan Date: 28 May 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL UTN:U1111-1149-0432 Status: Final EudraCT No.:NA Page: 1 of 30 Statistical Analysis Plan Trial ID: NN9535-4114 Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Author Biostatistics Semaglutide s.c. This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.This
    [Show full text]
  • ACNE 1743 Review ISOTR Adverse Effects
    Australasian Journal of Dermatology (2010) 51, 248–253 doi: 10.1111/j.1440-0960.2010.00657.x ORIGINAL ARTICLE Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoinajd_657 248..253 Marius Rademaker Tristram Clinic, Hamilton, New Zealand eczema (6) and pregnancy (2). There were no reported ABSTRACT instances of suicidal ideation or attempted suicide. Background/Objectives: Isotretinoin has revolu- Conclusions: Other than the two oral contraceptive tionized the management of acne vulgaris. However, failures, there were no serious adverse events concerns continue regarding the adverse effect recorded during this review period. Isotretinoin is a profile of isotretinoin. This study aims to review the very effective medication with a low adverse-effect adverse effects experienced by patients started on profile when used at lower doses. isotretinoin by a single dermatologist. Key words: acne vulgaris, depression, side-effect, Methods: Retrospective chart review of 1743 teratogenicity. patients started on isotretinoin for various dermato- logical conditions over a 6-year period. Details of the dose of isotretinoin used, concomitant medications, INTRODUCTION adverse effects and outcome were recorded. Isotretinoin (13-cis-retinoic acid) revolutionized the man- Results: One-fifth (18.5%) of patients reported no agement of acne vulgaris and various other skin disorders adverse effects during the study period. Cheilitis was when it was introduced in the 1980s.1,2 Isotretinoin was the the most commonly reported adverse effect, affecting first medication to modify the disease, rather than provide 78% of users, followed by eczema and tiredness, seen symptom control. In the last decade, it is estimated that in 12% each.
    [Show full text]
  • A Deep Learning System for Differential Diagnosis of Skin Diseases
    A deep learning system for differential diagnosis of skin diseases 1 1 1 1 1 1,2 † Yuan Liu ,​ Ayush Jain ,​ Clara Eng ,​ David H. Way ,​ Kang Lee ,​ Peggy Bui ,​ Kimberly Kanada ,​ ​ ​ ‡ ​ 1​ ​ 1 ​ 1 ​ Guilherme de Oliveira Marinho ,​ Jessica Gallegos ,​ Sara Gabriele ,​ Vishakha Gupta ,​ Nalini 1,3,§ 1 ​ ​ 4 ​ 1 ​ ​ 1 Singh ,​ Vivek Natarajan ,​ Rainer Hofmann-Wellenhof ,​ Greg S. Corrado ,​ Lily H. Peng ,​ Dale ​ ​ 1 1 ​ † 1, ​ 1, ​ 1, ​ R. Webster ,​ Dennis Ai ,​ Susan Huang ,​ Yun Liu *​ , R. Carter Dunn *​ *, David Coz *​ * ​ ​ ​ ​ ​ ​ Affiliations: 1 G​ oogle Health, Palo Alto, CA, USA 2 U​ niversity of California, San Francisco, CA, USA 3 M​ assachusetts Institute of Technology, Cambridge, MA, USA 4 M​ edical University of Graz, Graz, Austria † W​ ork done at Google Health via Advanced Clinical. ‡ W​ ork done at Google Health via Adecco Staffing. § W​ ork done at Google Health. *Corresponding author: [email protected] **These authors contributed equally to this work. Abstract Skin and subcutaneous conditions affect an estimated 1.9 billion people at any given time and remain the fourth leading cause of non-fatal disease burden worldwide. Access to dermatology care is limited due to a shortage of dermatologists, causing long wait times and leading patients to seek dermatologic care from general practitioners. However, the diagnostic accuracy of general practitioners has been reported to be only 0.24-0.70 (compared to 0.77-0.96 for dermatologists), resulting in over- and ​ ​ ​ ​ ​ ​ ​ under-referrals, delays in care, and errors in diagnosis and treatment. In this paper, we developed a deep learning system (DLS) to provide a differential diagnosis of skin conditions for clinical cases (skin photographs and associated medical histories).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,359,748 B1 Drugge (45) Date of Patent: Apr
    USOO7359748B1 (12) United States Patent (10) Patent No.: US 7,359,748 B1 Drugge (45) Date of Patent: Apr. 15, 2008 (54) APPARATUS FOR TOTAL IMMERSION 6,339,216 B1* 1/2002 Wake ..................... 250,214. A PHOTOGRAPHY 6,397,091 B2 * 5/2002 Diab et al. .................. 600,323 6,556,858 B1 * 4/2003 Zeman ............. ... 600,473 (76) Inventor: Rhett Drugge, 50 Glenbrook Rd., Suite 6,597,941 B2. T/2003 Fontenot et al. ............ 600/473 1C, Stamford, NH (US) 06902-2914 7,092,014 B1 8/2006 Li et al. .................. 348.218.1 (*) Notice: Subject to any disclaimer, the term of this k cited. by examiner patent is extended or adjusted under 35 Primary Examiner Daniel Robinson U.S.C. 154(b) by 802 days. (74) Attorney, Agent, or Firm—McCarter & English, LLP (21) Appl. No.: 09/625,712 (57) ABSTRACT (22) Filed: Jul. 26, 2000 Total Immersion Photography (TIP) is disclosed, preferably for the use of screening for various medical and cosmetic (51) Int. Cl. conditions. TIP, in a preferred embodiment, comprises an A6 IB 6/00 (2006.01) enclosed structure that may be sized in accordance with an (52) U.S. Cl. ....................................... 600/476; 600/477 entire person, or individual body parts. Disposed therein are (58) Field of Classification Search ................ 600/476, a plurality of imaging means which may gather a variety of 600/162,407, 477, 478,479, 480; A61 B 6/00 information, e.g., chemical, light, temperature, etc. In a See application file for complete search history. preferred embodiment, a computer and plurality of USB (56) References Cited hubs are used to remotely operate and control digital cam eras.
    [Show full text]
  • Prevalence of Paediatric Dermatoses Among Patients Attending Dermatology Outpatient Department in a Tertiary Care Hospital in Puducherry
    International Journal of Research in Dermatology Medasani V et al. Int J Res Dermatol. 2018 Aug;4(3):368-375 http://www.ijord.com DOI: http://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20183160 Original Research Article Prevalence of paediatric dermatoses among patients attending Dermatology outpatient department in a tertiary care hospital in Puducherry Varsha Medasani, Paquirissamy Oudeacoumar*, Rao Chitralekhya, Saurabh Krishna Misra Department of DVL, AVMC&H, Pondicherry, Puducherry, India Received: 04 April 2018 Revised: 30 May 2018 Accepted: 01 June 2018 *Correspondence: Dr. Paquirissamy Oudeacoumar, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Skin diseases are a major health problem in the paediatric age group and are associated with significant morbidity. Dermatoses in children are more influenced by socioeconomic status, dietary habits, climatic exposure and external environment as compared to adults. The present study was undertaken to know the prevalence of paediatric dermatoses among patients attending Dermatology outpatient department in a tertiary care hospital in Puducherry. Methods: All newly diagnosed, untreated male and female paediatric patients (from neonates to adolescents ≤19 years of age) attending Dermatology OPD, from October 2015 to September 2017 were evaluated to study the prevalence and patterns of paediatric dermatoses. The skin disorders were classified into groups like infections, infestations, eczemas, acne, hypersensitivity disorders, sweat gland disorders, pigmentary disorders, nevi, keratinisation disorders, hair and scalp disorders, papulosquamous disorders, bullous disorders, nail disorders, drug reactions, other dermatoses.
    [Show full text]
  • Mallory Prelims 27/1/05 1:16 Pm Page I
    Mallory Prelims 27/1/05 1:16 pm Page i Illustrated Manual of Pediatric Dermatology Mallory Prelims 27/1/05 1:16 pm Page ii Mallory Prelims 27/1/05 1:16 pm Page iii Illustrated Manual of Pediatric Dermatology Diagnosis and Management Susan Bayliss Mallory MD Professor of Internal Medicine/Division of Dermatology and Department of Pediatrics Washington University School of Medicine Director, Pediatric Dermatology St. Louis Children’s Hospital St. Louis, Missouri, USA Alanna Bree MD St. Louis University Director, Pediatric Dermatology Cardinal Glennon Children’s Hospital St. Louis, Missouri, USA Peggy Chern MD Department of Internal Medicine/Division of Dermatology and Department of Pediatrics Washington University School of Medicine St. Louis, Missouri, USA Mallory Prelims 27/1/05 1:16 pm Page iv © 2005 Taylor & Francis, an imprint of the Taylor & Francis Group First published in the United Kingdom in 2005 by Taylor & Francis, an imprint of the Taylor & Francis Group, 2 Park Square, Milton Park Abingdon, Oxon OX14 4RN, UK Tel: +44 (0) 20 7017 6000 Fax: +44 (0) 20 7017 6699 Website: www.tandf.co.uk All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP. Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention.
    [Show full text]
  • Unmasking the Mask: COVID-19 Manifestations of PPE Kits
    Our Dermatology Online Review Article UUnmaskingnmasking tthehe mmask:ask: CCOVID-19OVID-19 manifestationsmanifestations ooff PPPEPE kkitsits Santhanakrishnaan Soundarya, Srinivasan Sundaramoorthy Department of Dermatology, Chettinad Hospital and Research Institute, Kelambakkam, Tamil Nadu, India Corresponding author: Prof. Srinivasan Sundaramoorthy, MD PhD, E-mail: [email protected] ABSTRACT The world is now facing a new unexpected pandemic caused by SARS-CoV-2, which is a coronavirus that mainly targets the lungs, a very vital and sensitive organ of the body. Research and healthcare workers are still struggling to contain the disease and eradicate the virus. Before the invention of a vaccine, the virus may take at least several more millions of lives. On top of this, dermatologists are facing numerous challenges because of the regulations put forward by the WHO and local governments. This article discusses in detail various dermatological eruptions caused by the personal protective equipment (PPE) used in combating the disease. This should be an eye-opener for dermatologists worldwide. Key words: COVID-19; Pandemic; PPE kits; Masks INTRODUCTION chemical), immunological regulation, thermoregulation, sensory function, synthesis of vitamin D, wound repair, The COVID-19 pandemic, caused by the virus named and regeneration and is, above all, regarded as an organ SARS-CoV-2, was first reported in Wuhan, China, in of beauty. 2019, and then rapidly spread to more than 200 countries across the globe [1]. Its transmission mainly occurs This largest organ of the body harbors an ecosystem through droplets and aerosols spread by an affected of microorganisms (commensals) (Table 1). These person, whether symptomatic or asymptomatic, but organisms live in harmony with the host without the former being more contagious than the latter [2,3].
    [Show full text]